Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement

Multicenter Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Lymphoid Neoplasms

Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.176 ◽

2017 ◽

Vol 17 ◽

pp. S350-S351 ◽

Cited By ~ 1

Author(s):

Srdan Verstovsek ◽

Alessandro Rambaldi ◽

Christine Lihou ◽

Huiling Zhen ◽

Andreas Hochhaus

Keyword(s):

Growth Factor ◽

Multicenter Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Lymphoid Neoplasms

Abstract CT059: Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 for metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) alterations

10.1158/1538-7445.am2017-ct059 ◽

2017 ◽

Author(s):

Neal D. Shore ◽

Ekaterine Asatiani ◽

Christine F. Lihou ◽

Huiling Zhen ◽

Sumati Gupta

Keyword(s):

Growth Factor ◽

Urothelial Carcinoma ◽

Multicenter Study ◽

Fibroblast Growth ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Fgf Receptor

Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2)

10.1158/1538-7445.sabcs19-ot2-07-01 ◽

2020 ◽

Author(s):

Nick C. Turner ◽

Ian E. Krop ◽

Aditya Bardia ◽

Senthil Damodaran ◽

Miguel Martin ◽

...

Keyword(s):

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Fibroblast Growth ◽

Breast Cancers ◽

Phase 2 ◽

Phase 2 Study

603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Annals of Oncology ◽

10.1016/j.annonc.2020.08.717 ◽

2020 ◽

Vol 31 ◽

pp. S502-S503

Author(s):

M. Schuler ◽

J. Tabernero ◽

C. Massard ◽

G. Vasudeva Iyer ◽

O. Witt ◽

...

Keyword(s):

Growth Factor ◽

Phase Ii ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models

European Journal of Cancer ◽

10.1016/s0959-8049(20)31133-3 ◽

2020 ◽

Vol 138 ◽

pp. S25-S26

Author(s):

P. Mcsheehy ◽

J. Boult ◽

S. Robinson ◽

F. Bachmann ◽

M. El Shemerly ◽

...

Keyword(s):

Growth Factor ◽

Growth Factor Receptor ◽

Clinical Development ◽

Fibroblast Growth ◽

Phase 2 ◽

Angiogenic Activity ◽

Clinical Models ◽

Receptor Inhibitor

Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement

Hematology ◽

10.1080/10245332.2018.1446279 ◽

2018 ◽

Vol 23 (8) ◽

pp. 470-477 ◽

Cited By ~ 4

Author(s):

Kento Umino ◽

Shin-ichiro Fujiwara ◽

Takashi Ikeda ◽

Yumiko Toda ◽

Shoko Ito ◽

...

Keyword(s):

Growth Factor ◽

Clinical Outcomes ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Lymphoid Neoplasms

Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations

Annals of Oncology ◽

10.1093/annonc/mdw373.72 ◽

2016 ◽

Vol 27 ◽

pp. vi293 ◽

Cited By ~ 2

Author(s):

A.O. Siefker-Radtke ◽

B. Mellado ◽

K. Decaestecker ◽

J.M. Burke ◽

A. O'Hagan ◽

...

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Phase 2 ◽

Phase 2 Study ◽

Ongoing Phase ◽

Abstract A077: FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations

10.1158/1535-7163.targ-19-a077 ◽

2019 ◽

Author(s):

Luis Féliz ◽

Ekaterine Asatiani ◽

Christine Lihou ◽

Huiling Zhen ◽

Ian Silverman ◽

...

Keyword(s):

Growth Factor ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated ◽

Phase 2 Study of Second-Line Dovitinib (Tki258) in Patients with Fibroblast Growth Factor Receptor 2 (Fgfr2)-Mutated or -Nonmutated Advanced and/or Metastatic Endometrial Cancer

Annals of Oncology ◽

10.1093/annonc/mdu438.28 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 3

Author(s):

G.E. Konecny ◽

N. Finkler ◽

A.A. Garcia ◽

D. Lorusso ◽

P. Lee ◽

...

Keyword(s):

Endometrial Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Second Line ◽

Phase 2 ◽

Phase 2 Study

P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1232 ◽

2021 ◽

Vol 16 (3) ◽

pp. S673

Author(s):

S. Pant ◽

J. Tabernero ◽

C. Massard ◽

D.M. Hyman ◽

O. Witt ◽

...

Keyword(s):

Growth Factor ◽

Receptor Gene ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Phase 2 ◽

Phase 2 Study ◽